Compare Stocks: TYRA, KNSA, DNTH, and COGT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COGT Cogent Biosciences	$31.50 -5.1%	$37.36	$11.60 ▼ $43.73	$5.76B	0.31	1.51 million shs	4.60 million shs
DNTH Dianthus Therapeutics	$96.81 -4.3%	$107.03	$32.22 ▼ $117.88	$5.53B	1.24	598,178 shs	2.83 million shs
KNSA Kiniksa Pharmaceuticals International	$77.17 -2.7%	$74.58	$35.20 ▼ $82.94	$6.19B	0.09	473,868 shs	1.06 million shs
TYRA Tyra Biosciences	$25.73 +5.3%	$27.66	$12.38 ▼ $40.65	$1.46B	0.73	1.09 million shs	2.07 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COGT Cogent Biosciences	-5.09%	-5.72%	-14.52%	-8.80%	+154.85%
DNTH Dianthus Therapeutics	-4.26%	-8.84%	-14.85%	+17.36%	+149.00%
KNSA Kiniksa Pharmaceuticals International	-2.72%	+1.18%	-4.49%	+40.03%	+117.81%
TYRA Tyra Biosciences	+5.32%	+16.80%	-4.03%	-9.15%	+111.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COGT Cogent Biosciences	$31.50 -5.1%	$37.36	$11.60 ▼ $43.73	$5.76B	0.31	1.51 million shs	4.60 million shs
DNTH Dianthus Therapeutics	$96.81 -4.3%	$107.03	$32.22 ▼ $117.88	$5.53B	1.24	598,178 shs	2.83 million shs
KNSA Kiniksa Pharmaceuticals International	$77.17 -2.7%	$74.58	$35.20 ▼ $82.94	$6.19B	0.09	473,868 shs	1.06 million shs
TYRA Tyra Biosciences	$25.73 +5.3%	$27.66	$12.38 ▼ $40.65	$1.46B	0.73	1.09 million shs	2.07 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COGT Cogent Biosciences	-5.09%	-5.72%	-14.52%	-8.80%	+154.85%
DNTH Dianthus Therapeutics	-4.26%	-8.84%	-14.85%	+17.36%	+149.00%
KNSA Kiniksa Pharmaceuticals International	-2.72%	+1.18%	-4.49%	+40.03%	+117.81%
TYRA Tyra Biosciences	+5.32%	+16.80%	-4.03%	-9.15%	+111.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COGT Cogent Biosciences	2.75	Moderate Buy	$51.56	63.67% Upside
DNTH Dianthus Therapeutics	2.93	Moderate Buy	$129.83	34.11% Upside
KNSA Kiniksa Pharmaceuticals International	2.80	Moderate Buy	$87.38	13.23% Upside
TYRA Tyra Biosciences	2.77	Moderate Buy	$47.88	86.07% Upside

Current Analyst Ratings Breakdown

Latest TYRA, KNSA, DNTH, and COGT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	COGT Cogent Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$55.00
9/15/2026	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
9/11/2026	DNTH Dianthus Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$135.00
9/10/2026	TYRA Tyra Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/10/2026	TYRA Tyra Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$53.00
9/10/2026	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$45.00 ➝ $30.00
9/8/2026	TYRA Tyra Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$56.00
9/4/2026	DNTH Dianthus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$156.00
9/4/2026	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$45.00
8/17/2026	COGT Cogent Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$52.00 ➝ $55.00
8/13/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$3.84 per share	N/A
DNTH Dianthus Therapeutics	$2.04M	2,594.41	N/A	N/A	$11.41 per share	8.48
KNSA Kiniksa Pharmaceuticals International	$677.56M	8.89	$0.77 per share	99.94	$7.44 per share	10.37
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$4.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COGT Cogent Biosciences	-$328.94M	-$2.16	N/A	N/A	N/A	N/A	-84.47%	-47.72%	11/6/2026 (Estimated)
DNTH Dianthus Therapeutics	-$162.34M	-$4.15	N/A	N/A	N/A	-10,096.95%	-22.53%	-21.55%	11/5/2026 (Estimated)
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	79.56	37.28	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)
TYRA Tyra Biosciences	-$119.95M	-$2.40	N/A	N/A	N/A	N/A	-46.39%	-43.07%	11/4/2026 (Estimated)

Latest TYRA, KNSA, DNTH, and COGT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	COGT Cogent Biosciences	-$0.5550	-$0.52	+$0.0350	-$0.52	$0.00 million	N/A
8/4/2026	Q2 2026	DNTH Dianthus Therapeutics	-$0.8463	-$0.90	-$0.0537	-$0.90	$0.30 million	$0.76 million
8/4/2026	Q2 2026	TYRA Tyra Biosciences	-$0.6499	-$0.69	-$0.0401	-$0.69	N/A	N/A
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COGT Cogent Biosciences	0.48	13.57	13.57
DNTH Dianthus Therapeutics	N/A	26.10	26.10
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49
TYRA Tyra Biosciences	N/A	14.90	14.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COGT Cogent Biosciences	N/A
DNTH Dianthus Therapeutics	47.53%
KNSA Kiniksa Pharmaceuticals International	53.95%
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
COGT Cogent Biosciences	6.59%
DNTH Dianthus Therapeutics	3.02%
KNSA Kiniksa Pharmaceuticals International	51.98%
TYRA Tyra Biosciences	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COGT Cogent Biosciences	258	173.52 million	162.09 million	Optionable
DNTH Dianthus Therapeutics	92	54.67 million	53.02 million	Optionable
KNSA Kiniksa Pharmaceuticals International	366	78.02 million	37.47 million	Optionable
TYRA Tyra Biosciences	87	59.68 million	52.22 million	Optionable

TYRA, KNSA, DNTH, and COGT Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

September 17 at 10:00 AM | prnewswire.com

Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

September 16 at 5:31 PM | insidermonkey.com

Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets

September 16 at 12:45 PM | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

September 15, 2026 | globenewswire.com

Squarepoint Ops LLC Purchases 43,311 Shares of Tyra Biosciences, Inc. $TYRA

September 15, 2026 | marketbeat.com

Tyra Bioscience Shares Rise After Pricing $400 Million Offering

September 14, 2026 | marketscreener.comM

Tyra Biosciences Shares Rise After $400 Million Offering Prices

September 14, 2026 | marketwatch.com

Biotech Stocks On The Move: Tyra, Nasus, Bionano & Tenaya Make Gains

September 14, 2026 | rttnews.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up - Time to Buy?

September 14, 2026 | marketbeat.com

Tyra Prices $400 Mln Underwritten Offering Of Stock & Warrants To Advance Dabogratinib 3x3

September 14, 2026 | rttnews.com

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

September 14, 2026 | prnewswire.com

Tyra Biosciences (NASDAQ:TYRA) Trading Down 5.6% Following Analyst Downgrade

September 13, 2026 | americanbankingnews.com

Insider Buying: Tyra Biosciences (NASDAQ:TYRA) Director Acquires 972 Shares of Stock

September 12, 2026 | insidertrades.com

HC Wainwright Has Lowered Expectations for Tyra Biosciences (NASDAQ:TYRA) Stock Price

September 12, 2026 | americanbankingnews.com

Tyra Biosciences (NASDAQ:TYRA) Director Buys $20,003.76 in Stock

September 11, 2026 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Shares Down 5.6% After Analyst Downgrade

September 11, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

September 10, 2026 | prnewswire.com

Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib

September 10, 2026 | thepharmaletter.comT

Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 5.6% - Still a Buy?

September 10, 2026 | marketbeat.com

Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript

September 10, 2026 | seekingalpha.com

Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC - Slideshow

September 10, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA, KNSA, DNTH, and COGT Company Descriptions

Cogent Biosciences NASDAQ:COGT

$31.50 -1.69 (-5.09%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$32.14 +0.64 (+2.03%)

As of 09/18/2026 07:30 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Dianthus Therapeutics NASDAQ:DNTH

$96.81 -4.31 (-4.26%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$96.82 +0.02 (+0.02%)

As of 09/18/2026 07:30 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$77.17 -2.16 (-2.72%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$77.17 +0.00 (+0.00%)

As of 09/18/2026 07:30 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Tyra Biosciences NASDAQ:TYRA

$25.73 +1.30 (+5.32%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$25.74 +0.02 (+0.06%)

As of 09/18/2026 07:34 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TYRA, KNSA, DNTH, and COGT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TYRA, KNSA, DNTH, and COGT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TYRA, KNSA, DNTH, and COGT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA, KNSA, DNTH, and COGT Company Descriptions

Cogent Biosciences NASDAQ:COGT

Dianthus Therapeutics NASDAQ:DNTH

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Tyra Biosciences NASDAQ:TYRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TYRA, KNSA, DNTH, and COGT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TYRA, KNSA, DNTH, and COGT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TYRA, KNSA, DNTH, and COGT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA, KNSA, DNTH, and COGT Company Descriptions

Cogent Biosciences NASDAQ:COGT

Dianthus Therapeutics NASDAQ:DNTH

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Tyra Biosciences NASDAQ:TYRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools